Singapore: Temasek backs $20m Series A in bioengineering firm Medisix

Singapore: Temasek backs $20m Series A in bioengineering firm Medisix

T-lymphocytes attack a migrating cancer cell. Visual from Medisix's website.

Singapore-based MediSix Therapeutics, which is developing cellular therapies targeting T-cell leukaemia and lymphoma, announced that it has raised $20 million in Series A financing backed by state investment arm Temasek Holdings.

MediSix said proceeds from the Series A financing, which was led by global venture capital firm Lightstone Ventures and joined by Osage University Partners, will be used to expand the startup’s team, advance product development, and initiate early pre-clinical studies.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter